Alzheimer's Drugs Now Slow Disease by 3+ Years

After 30 years of research, Alzheimer's treatments are finally working in ways that make a real difference for patients and families.

Pioneering researcher John Hardy, who helped unlock the mystery of how Alzheimer's damages the brain in the 1990s, announced at WIRED Health that new drugs like Lecanemab can now extend the timeline of the disease from eight years to 11 or 12 years. That's three extra years of memories, independence, and time with loved ones.

Hardy discovered that protein deposits called amyloid plaques disrupt brain cells and trigger harmful inflammation. His breakthrough led to the development of antibodies that can actually remove these plaques from patients' brains, something scientists struggled to achieve for decades.

Clinical trials published in 2022 showed Lecanemab could slow cognitive decline for the first time ever. Another drug called Gantenerumab recently showed similar promise after researchers discovered higher doses work better. Both treatments are now available to patients in the United States through FDA approval and Medicare coverage.

The science is accelerating, but Hardy says the next breakthrough requires more than lab work. Better diagnosis tools could catch Alzheimer's earlier, similar to how cholesterol tests help prevent heart disease. Right now, only about 60 percent of people diagnosed with dementia actually have Alzheimer's disease specifically.

Blood tests using biomarkers can identify who will develop Alzheimer's before symptoms appear. Catching the disease early means treatments can work before too much damage occurs.

The Ripple Effect

Hardy's optimism extends beyond individual patients to entire healthcare systems. Investment in dementia services could help millions of families worldwide get accurate diagnoses and access to these life-changing treatments.

In the UK, only private patients can currently access these new drugs, but advocacy is growing for broader coverage. As more countries approve and fund these treatments, the pressure builds for better dementia care everywhere.

Scientists are already working on more powerful versions of these medications. Combined with earlier detection through simple blood tests, the next generation of treatments could stop Alzheimer's entirely rather than just slow it down.

Hardy admits he was "naively optimistic" three decades ago about how quickly a cure would arrive, but his persistence paid off. The drugs aren't perfect yet, but they prove the approach works and improvement is possible.

For families watching loved ones slip away to Alzheimer's, three extra years together represents precious time that didn't exist before.